Efficacy of GnRH antagonists in the treatment of uterine fibroids: a meta-analysis
Archives of Gynecology and Obstetrics · 16.01.2025 · 311 (3) · 685-696
DOI: 10.1007/s00404-025-07932-9 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Archives of Gynecology and Obstetrics, online erschienen am 16.01.2025. Verfasst von María Jésus Sánchez Martín und 3 weiteren Autor:innen. Beteiligte Einrichtung: Gynecology Department, Hospital Clínico San Carlos, Calle del Prof Martín Lagos, S/N, 28040, Madrid, Spain. Hauptthemen laut MEDLINE: Gonadotropin-Releasing Hormone, Leiomyoma, Uterine Neoplasms, Hormone Antagonists. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
PURPOSE: Uterine fibroids are the most common pelvic tumors in women, representing the primary indication of hysterectomy. Gonadotropin-releasing hormone (GnRH) antagonists represent a new therapeutic option for premenopausal women. The aim of this review is to evaluate the efficacy and safety of GnRH antagonists in the treatment of uterine fibroids (size reduction and symptom control). METHODS: A review of studies from electronic databases (PubMed and Cochrane Central) published up to December 2023 was performed. Eleven randomized clinical trials with a total of 4164 patients were included in the review, which evaluated GnRH antagonists (Relugolix, Elagolix, Linzagolix and Cetrorelix) against placebo or GnRH agonists in premenopausal women with uterine fibroids and heavy menstrual bleeding. RESULTS: The results of the measures evaluated to determine the efficacy and safety of GnRH antagonists versus placebo are favorable for the variables of control of uterine bleeding (Relative risk (RR) = 5.09; 95% CI 3.19 to 8.14), percentage reduction of fibroid volume (Mean difference (MD) = -27.36; 95% CI -38.89 to -15.83) and lower reduction of bone density (MD -0.35; 95% CI -0.47 to -0.24). The results do not allow us to conclude whether there are differences between the alternatives compared in the control of vasomotor symptoms. CONCLUSIONS: GnRH antagonists represent an effective alternative for uterine fibroids treatment as they allow a superior reduction in menstrual bleeding and uterine fibroid volume compared to the placebo group.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gynecology Department, Hospital Clínico San Carlos, Calle del Prof Martín Lagos, S/N, 28040, Madrid, Spain.
- Instituto de Investigación Sanitaria Hospital Clínico San Carlos de Madrid (IdISSC), 28040, Madrid, Spain.
- Gynecology Department, Hospital Clínico San Carlos, Calle del Prof Martín Lagos, S/N, 28040, Madrid, Spain. icristobal@salud.madrid.org.
ORCID-Profile: María Jésus Sánchez Martín, Cristina Huerga López, Ignacio Cristóbal García, Ignacio Cristóbal Quevedo
Zitieren
APA
Sánchez Martín, M. J., Huerga López, C., Cristóbal García, I., & Cristóbal Quevedo, I. (2025). Efficacy of GnRH antagonists in the treatment of uterine fibroids: a meta-analysis. Archives of Gynecology and Obstetrics, 311(3), 685-696. https://doi.org/10.1007/s00404-025-07932-9
Vancouver
Sánchez Martín MJ, Huerga López C, Cristóbal García I, Cristóbal Quevedo I. Efficacy of GnRH antagonists in the treatment of uterine fibroids: a meta-analysis. Archives of Gynecology and Obstetrics. 2025;311(3):685-696. doi:10.1007/s00404-025-07932-9
BibTeX
@article{SnchezMartn2025,
author = {Sánchez Martín, María Jésus and Huerga López, Cristina and Cristóbal García, Ignacio and Cristóbal Quevedo, Ignacio},
title = {Efficacy of GnRH antagonists in the treatment of uterine fibroids: a meta-analysis},
journal = {Archives of Gynecology and Obstetrics},
year = {2025},
volume = {311},
number = {3},
pages = {685--696},
doi = {10.1007/s00404-025-07932-9}
}
EUVIMED